ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
Hørsholm, Denmark, 18 June 2024 – ExpreS2ion Biotech Holding AB’s ("ExpreS2ion" or the "Company") (NASDAQ First North: EXPRS2) announces that its recent webinar covering the 2024 rights issue, hosted by CEO Bent Frandsen and CFO Keith Alexander, is now available for on-demand viewing. The webinar provided insights into the background and rationale for the rights issue, detailed the intended use of proceeds, outlined the structure of the offering, and explained how to participate. Additionally, CEO Bent Frandsen has recently delivered significant presentations at major life science forums, highlighting the progress and potential of the ES2B-C001 therapeutic HER2+ breast cancer vaccine.
Background and rationale for the 2024 rights issue
During the webinar, CEO Bent Frandsen elaborated on the strategic importance of the rights issue. He emphasized that the additional capital will bolster the Company's ongoing efforts in advancing its pipeline of innovative therapeutics and vaccines. In particular, this capital injection is critical for initiating the phase I clinical trial of ES2B-C001, the Company’s groundbreaking therapeutic HER2+ breast cancer vaccine.
CEO Bent Frandsen’s presentations with emphasis on ES2B-C001:
- H.C. Andersen Capital Life Science Seminar on 4 June 2024, Watch the presentation.
- BioStock Global Forum on 30 May 2024, Watch the presentation.
Additional resources
For comprehensive information about the 2024 Rights Issue, including the full prospectus and a step-by-step subscription guide, visit the ExpreS2ion investor relations site, under IPO and Rights Issues. Presentation recordings providing further insights into the development and potential of the ES2B-C001 vaccine are also available on the investor relations website, under Presentations.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.
